• Inovio Pharmaceuticals priced a public offering expected to raise approximately $75 million gross, excluding any exercise of the underwriters' option.
• The offering includes 58,747,235 common shares at $1.05 each, before underwriting discounts and commissions.
• Pre-funded warrants to purchase 12,681,337 common shares were priced at $1.049 each, before underwriting discounts and commissions.
• Underwriters have a 30-day option to purchase 10,714,285 additional common shares at the offering price, less underwriting discounts and commissions.
• The offering is expected to close on or about November 9, 2026, subject to customary closing conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inovio Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611052318PR_NEWS_USPR_____PH91026) on November 06, 2026, and is solely responsible for the information contained therein.